The preventable burden is a delivery problem, from stigma to treatment failure

Stigma blocks the first step

In a preprint based on a survey of women living in urban Nepal, formal education was associated with lower cervical cancer stigma scores, and awareness that cervical cancer is preventable and treatable was also associated with lower stigma. m:…5521

The preprint also reports higher stigma scores for Janjati women and for Dalit and Madhesi women than for Brahmin and Chettri women. The pattern suggests that general awareness campaigns may miss the groups carrying the heaviest stigma, and that specific disease knowledge, rather than name recognition alone, tracks with lower stigma. m:…5521

That distinction matters for prevention. If stigma discourages engagement with screening, then a programme that raises awareness of the disease name without explaining prevention, treatability, signs and symptoms leaves the barrier largely intact, according to the associations reported in the preprint. m:…5521

A large preventable share, on paper

A second preprint models the expected and potentially preventable burden of infection-related cancer among newly arrived migrants in the European Union. It projects 635,000 lifetime cases of infection-related cancers, covering liver, cervical and gastric cancers, in that population. m:…3515

The modelled prevention shares are large. ECDC-recommended hepatitis interventions could prevent 15 percent of liver cancer cases among newly arrived migrants, HPV vaccination could prevent 65 percent of cervical cancer cases and cervical screening 60 percent among eligible migrants, and H. pylori screen-and-treat interventions could prevent 44 percent of gastric cancer cases among all newly arrived migrants. m:…3515

The preventable share is therefore a measure of what screening and vaccination could do if delivered, not a forecast of what will happen without delivery systems to match. m:…3515

Treatment failure drives transmission

A third preprint, an agent-based modelling study of tuberculosis in India, shows the same delivery gap from the treatment side. Treatment failure, with or without diagnostic failure, accounted for 63 percent of infectiousness-weighted tuberculosis burden in the model. m:…1309

The time dimension explains why that share is so large. Median effective infectious time was 16 months for patients with treatment failure, compared with 3 months for those with no failure. A patient who starts treatment but does not complete it successfully therefore remains infectious far longer than a patient whose treatment succeeds, which changes how burden should be counted. m:…1309

The preprint tests a combined response rather than a single fix. A package of active case finding, diagnostic improvement and treatment support reduced projected 2035 tuberculosis incidence by 34 percent, with a 95 percent confidence interval of 31 to 36 percent. No single element of that package, on its own, is presented as the answer. m:…1309

The common thread

Read together, the three preprints describe prevention as a chain with several weak links. Knowledge and lower stigma must come before screening in Nepal, screening and vaccination must actually reach newly arrived migrants in the EU, and diagnosis must be followed by treatment support that prevents failure in India. A break at any link leaves the burden in place even when the intervention itself is known. m:…5521 m:…3515 m:…1309

Each study is a preprint, so its numbers should be read as modelled or surveyed estimates awaiting further validation, not as settled programme results. That is a further reason to treat the 34 percent reduction as a modelled scenario rather than a promised result. m:…1309